![](https://unicorn-nest.com/wp-content/uploads/avatars/person/keyperson_jafco_life_science_ko_minamikurosawa.jpg?x55332)
The leading representative office of defined VC is situated in the Tokyo. The company was established in Asia in Japan.
We can highlight the next thriving fund investment areas, such as Therapeutics, Health Care. Among the various public portfolio startups of the fund, we may underline Kythera Biopharmaceuticals, Lucid Motors, Catalyst Biosciences For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Jafco Life Science, startups are often financed by Versant Ventures, Pittsburgh Life Sciences Greenhouse, Wilson Sonsini Goodrich & Rosati. The meaningful sponsors for the fund in investment in the same round are WS Investments, Versant Ventures, Scottish Widows Investment Partnership. In the next rounds fund is usually obtained by Sofinnova Investments, RCT BioVentures, Novartis Venture Fund.
Opposing the other organizations, this Jafco Life Science works on 21 percentage points more the average amount of lead investments. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2003. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2012.
Besides them, we counted 5 critical employees of this fund in our database.
Related Funds
Funds with similar focus
Fund Name | Location |
Anchorless Bangladesh | New York, New York, United States |
Funding London | England, London, United Kingdom |
HealthXCapital | Central Region, Singapore, Singapore |
Medical Mutual | Cleveland, Ohio, United States |
Qingyong Capital Management | China, Hangzhou, Zhejiang |
Russell Westbrook Enterprises | - |
Stonecourt Capital | New York, New York, United States |
ViKtoria Business Angels Network | Kenya, Nairobi, Nairobi Area |
Xunfang Fund | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Complexa | $62M | 26 Jul 2017 | Pittsburgh, Pennsylvania, United States | ||
Complexa | $13M | 05 Jun 2014 | Pittsburgh, Pennsylvania, United States | ||
Kythera Biopharmaceuticals | $30M | 19 May 2008 | California, United States | ||
Catalyst Biosciences | $60M | 20 Mar 2003 | South San Francisco, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Complexa | $62M | 26 Jul 2017 | Pittsburgh, Pennsylvania, United States | ||
Complexa | $13M | 05 Jun 2014 | Pittsburgh, Pennsylvania, United States | ||
Kythera Biopharmaceuticals | $30M | 19 May 2008 | California, United States | ||
Catalyst Biosciences | $60M | 20 Mar 2003 | South San Francisco, California, United States |